Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer

Monica Santimaria, Giovanni Moscatelli, Giuseppe L. Viale, Leonardo Giovannoni, Giovanni Neri, Francesca Viti, Alessandra Leprini, Laura Borsi, Patrizia Castellani, Luciano Zardi, Dario Neri, Pietro Riva

Research output: Contribution to journalArticle

265 Citations (Scopus)

Abstract

Purpose: ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling. We demonstrated previously the possibility to target and selectively deliver therapeutic substances to tumor vasculature in experimental animal models using a human recombinant antibody fragment, L19, specific for the ED-B domain of fibronectin. Here we evaluate the possibility of targeting primary tumors and metastatic lesions in cancer patients through immunoscintigraphy using 123I-labeled dimeric L19 [L19(scFv)2]. Experimental Design: Twenty patients (34-79 years of age) with lung, colorectal, or brain cancer, whose tumors had been confirmed by imaging techniques and/or histologically, were admitted to the immunoscintigraphic investigation. Results: The dimeric L19 antibody selectively localized in tumor lesions in aggressive types of lung cancer and colorectal cancer. Because ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling, L19(scFv)2 is able to distinguish between quiescent and actively growing lesions. No side effects were observed. Conclusions: The ability of L19(scFv)2 to target tumors in patients provides the foundations for new therapeutic applications, in which the L19 antibody is engineered to selectively deliver bioactive molecules to primary tumors as well as to metastases.

Original languageEnglish
Pages (from-to)571-579
Number of pages9
JournalClinical Cancer Research
Volume9
Issue number2
Publication statusPublished - Feb 1 2003

Fingerprint

Fibronectins
Neoplasms
Colorectal Neoplasms
Lung Neoplasms
Immunoglobulin Fragments
Antibodies
Growth
Brain Neoplasms
Research Design
Animal Models
Neoplasm Metastasis
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Santimaria, M., Moscatelli, G., Viale, G. L., Giovannoni, L., Neri, G., Viti, F., ... Riva, P. (2003). Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clinical Cancer Research, 9(2), 571-579.

Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. / Santimaria, Monica; Moscatelli, Giovanni; Viale, Giuseppe L.; Giovannoni, Leonardo; Neri, Giovanni; Viti, Francesca; Leprini, Alessandra; Borsi, Laura; Castellani, Patrizia; Zardi, Luciano; Neri, Dario; Riva, Pietro.

In: Clinical Cancer Research, Vol. 9, No. 2, 01.02.2003, p. 571-579.

Research output: Contribution to journalArticle

Santimaria, M, Moscatelli, G, Viale, GL, Giovannoni, L, Neri, G, Viti, F, Leprini, A, Borsi, L, Castellani, P, Zardi, L, Neri, D & Riva, P 2003, 'Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer', Clinical Cancer Research, vol. 9, no. 2, pp. 571-579.
Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clinical Cancer Research. 2003 Feb 1;9(2):571-579.
Santimaria, Monica ; Moscatelli, Giovanni ; Viale, Giuseppe L. ; Giovannoni, Leonardo ; Neri, Giovanni ; Viti, Francesca ; Leprini, Alessandra ; Borsi, Laura ; Castellani, Patrizia ; Zardi, Luciano ; Neri, Dario ; Riva, Pietro. / Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 2. pp. 571-579.
@article{1b2199ce51124d7c808c9dc301517104,
title = "Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer",
abstract = "Purpose: ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling. We demonstrated previously the possibility to target and selectively deliver therapeutic substances to tumor vasculature in experimental animal models using a human recombinant antibody fragment, L19, specific for the ED-B domain of fibronectin. Here we evaluate the possibility of targeting primary tumors and metastatic lesions in cancer patients through immunoscintigraphy using 123I-labeled dimeric L19 [L19(scFv)2]. Experimental Design: Twenty patients (34-79 years of age) with lung, colorectal, or brain cancer, whose tumors had been confirmed by imaging techniques and/or histologically, were admitted to the immunoscintigraphic investigation. Results: The dimeric L19 antibody selectively localized in tumor lesions in aggressive types of lung cancer and colorectal cancer. Because ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling, L19(scFv)2 is able to distinguish between quiescent and actively growing lesions. No side effects were observed. Conclusions: The ability of L19(scFv)2 to target tumors in patients provides the foundations for new therapeutic applications, in which the L19 antibody is engineered to selectively deliver bioactive molecules to primary tumors as well as to metastases.",
author = "Monica Santimaria and Giovanni Moscatelli and Viale, {Giuseppe L.} and Leonardo Giovannoni and Giovanni Neri and Francesca Viti and Alessandra Leprini and Laura Borsi and Patrizia Castellani and Luciano Zardi and Dario Neri and Pietro Riva",
year = "2003",
month = "2",
day = "1",
language = "English",
volume = "9",
pages = "571--579",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer

AU - Santimaria, Monica

AU - Moscatelli, Giovanni

AU - Viale, Giuseppe L.

AU - Giovannoni, Leonardo

AU - Neri, Giovanni

AU - Viti, Francesca

AU - Leprini, Alessandra

AU - Borsi, Laura

AU - Castellani, Patrizia

AU - Zardi, Luciano

AU - Neri, Dario

AU - Riva, Pietro

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Purpose: ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling. We demonstrated previously the possibility to target and selectively deliver therapeutic substances to tumor vasculature in experimental animal models using a human recombinant antibody fragment, L19, specific for the ED-B domain of fibronectin. Here we evaluate the possibility of targeting primary tumors and metastatic lesions in cancer patients through immunoscintigraphy using 123I-labeled dimeric L19 [L19(scFv)2]. Experimental Design: Twenty patients (34-79 years of age) with lung, colorectal, or brain cancer, whose tumors had been confirmed by imaging techniques and/or histologically, were admitted to the immunoscintigraphic investigation. Results: The dimeric L19 antibody selectively localized in tumor lesions in aggressive types of lung cancer and colorectal cancer. Because ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling, L19(scFv)2 is able to distinguish between quiescent and actively growing lesions. No side effects were observed. Conclusions: The ability of L19(scFv)2 to target tumors in patients provides the foundations for new therapeutic applications, in which the L19 antibody is engineered to selectively deliver bioactive molecules to primary tumors as well as to metastases.

AB - Purpose: ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling. We demonstrated previously the possibility to target and selectively deliver therapeutic substances to tumor vasculature in experimental animal models using a human recombinant antibody fragment, L19, specific for the ED-B domain of fibronectin. Here we evaluate the possibility of targeting primary tumors and metastatic lesions in cancer patients through immunoscintigraphy using 123I-labeled dimeric L19 [L19(scFv)2]. Experimental Design: Twenty patients (34-79 years of age) with lung, colorectal, or brain cancer, whose tumors had been confirmed by imaging techniques and/or histologically, were admitted to the immunoscintigraphic investigation. Results: The dimeric L19 antibody selectively localized in tumor lesions in aggressive types of lung cancer and colorectal cancer. Because ED-B fibronectin is expressed only during angiogenic processes and in tissues undergoing growth and/or extensive remodeling, L19(scFv)2 is able to distinguish between quiescent and actively growing lesions. No side effects were observed. Conclusions: The ability of L19(scFv)2 to target tumors in patients provides the foundations for new therapeutic applications, in which the L19 antibody is engineered to selectively deliver bioactive molecules to primary tumors as well as to metastases.

UR - http://www.scopus.com/inward/record.url?scp=0037314650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037314650&partnerID=8YFLogxK

M3 - Article

C2 - 12576420

AN - SCOPUS:0037314650

VL - 9

SP - 571

EP - 579

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -